10-K: Longeveron Faces Liquidity Challenges Amid R&D Expansion

Longeveron Inc. reported a widened net loss for fiscal year 2025 and substantial doubt about its ability to continue as a going concern, despite advancing its lead product candidate, laromestrocel, in multiple clinical programs.

Summary

• Longeveron is a clinical-stage biotechnology company developing regenerative medicines, with its lead investigational product candidate being laromestrocel (Lomecel-B).
• The company is pursuing four potential indications for laromestrocel: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty.
• As of December 2025, five U.S. clinical studies of laromestrocel have been completed, and one fully enrolled, ongoing clinical trial is the ELPIS II Phase 2b for HLHS.
• A strategic decision has been made to pursue commercial manufacturing for HLHS through a third-party Contract Development and Manufacturing Organization (CDMO), rather than renovating the existing Miami facility for commercial-scale production.
• The Miami manufacturing facility will continue to support clinical development, research, and early-phase manufacturing for current and future clinical trials.
• The clinical trial in Japan for Aging-related Frailty was discontinued in April 2024.
• An Investigational New Drug (IND) application for pediatric DCM became effective in July 2025, with plans for a single pivotal Phase 2 registrational clinical trial in 2027.
• The net loss increased to $22.7 million in 2025 from $16.0 million in 2024.
• Total revenues decreased by 50% to $1.2 million in 2025 from $2.4 million in 2024, primarily due to lower participant demand for the Bahamas Registry Trial and reduced contract manufacturing services.
• Cash and cash equivalents were $4.7 million as of December 31, 2025.
• An initial closing of a private placement financing in March 2026 raised approximately $15.9 million in gross proceeds, which, combined with existing cash, is expected to fund operations into the fourth quarter of 2026.
• The company had an accumulated deficit of $132.3 million as of December 31, 2025, and there is substantial doubt about its ability to continue as a going concern.
• Cost-savings efforts, including temporary compensation reductions for the CEO, Executive Chairman/CSO (50%), and C-suite officers (25%), were implemented effective February 16, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period for Longeveron, marked by significant financial losses, declining revenue, and a stated going concern risk. While clinical programs show progress and regulatory designations are positive, the company's immediate liquidity and need for substantial future funding create considerable uncertainty.

Positives

• Laromestrocel received Regenerative Medicine Advanced Therapy (RMAT) Designation and Fast Track designation from the FDA for the treatment of mild Alzheimer's disease in July 2024.
• The FDA granted Rare Pediatric Disease Designation (RPD), Orphan Drug Designation (ODD), and Fast Track Designation for laromestrocel for the treatment of Hypoplastic Left Heart Syndrome (HLHS).
• A positive Type B Meeting with the FDA in March 2025 supported the advancement of laromestrocel for mild AD, with foundational alignment on a proposed single, pivotal, seamless adaptive Phase 2/3 clinical trial design, and the FDA agreed to consider a Biologics License Application (BLA) based on positive interim trial results.
• Enrollment for the pivotal Phase 2b ELPIS II study for HLHS was completed in June 2025, with top-line data anticipated in the third quarter of 2026.
• The IND application for laromestrocel as a potential treatment for pediatric Dilated Cardiomyopathy (DCM) became effective in July 2025, allowing for direct progression to a single pivotal Phase 2 registrational clinical trial in 2027.
• The FDA's approval of Mesoblast's Ryoncil, an allogeneic bone marrow-derived MSC therapy, is viewed as a positive development for Longeveron, as it belongs to the same class of cell therapy as laromestrocel.
• The company received a $250,000 Milestone 1 Award in the XPRIZE Healthspan competition in May 2025.
• An initial closing of a private placement transaction in March 2026 successfully raised approximately $15.9 million in gross proceeds.

Negatives

• The net loss increased to $22.7 million for the year ended December 31, 2025, from $16.0 million in 2024, representing a 41% increase.
• Total revenues decreased by 50% to $1.2 million in 2025 from $2.4 million in 2024, driven by lower demand for the Bahamas Registry Trial and reduced contract manufacturing services.
• The company reported an accumulated deficit of $132.3 million as of December 31, 2025.
• There is substantial doubt about the company's ability to continue as a going concern, as stated by both management and the independent registered public accounting firm.
• Cash and cash equivalents significantly decreased from $19.2 million at December 31, 2024, to $4.7 million at December 31, 2025.
• Current operating plans, even with the recent $15.9 million private placement, are only expected to fund operations into the fourth quarter of 2026, indicating a persistent need for additional capital.
• The clinical trial in Japan for Aging-related Frailty was discontinued in April 2024.
• The company received a notice from Nasdaq on September 22, 2025, regarding non-compliance with the $1.00 minimum bid price requirement for continued listing.
• As of March 4, 2026, the company is temporarily non-compliant with Nasdaq Listing Rule 5605(c)(2)(A) due to the resignation of its audit committee financial expert.
• Temporary compensation reductions of 50% for the CEO and Executive Chairman/CSO, and 25% for C-suite officers, were implemented effective February 16, 2026, as part of cost-savings efforts.

Risks

• Ongoing challenges with liquidity and access to capital, and the need to raise additional capital, which may have a dilutive impact on investors.
• A history of losses and uncertainty about achieving profitability or continuing as a going concern.
• A limited operating history and no products approved for commercial sale, making it difficult to evaluate current business and predict future success.
• Absence of FDA-approved allogeneic, cell-based therapies for Aging-related Frailty, Alzheimer's disease (AD), Hypoplastic Left Heart Syndrome (HLHS), pediatric Dilated Cardiomyopathy (DCM), or other cardiac-related indications, which could complicate and delay FDA approval.
• Inadequate protection of trade secrets and patent position could lead to direct competition.
• Termination of certain license agreements could adversely affect the ability to continue clinical trials and commercially market products.
• Uncertainty regarding proper assignment of all intellectual property to the Company.
• Intellectual property rights may not address all potential threats to competitive advantage.
• Substantial dependence on the successful development, regulatory approval, and commercialization of laromestrocel.
• Inability to successfully develop and commercialize investigational product candidates and obtain necessary regulatory approvals may prevent generation of sufficient revenues.
• Chemistry, Manufacturing and Controls (CMC) readiness and ability to manufacture laromestrocel for commercialization may require significant additional investment, be delayed, or be unsuccessful.
• Even if clinical development is completed, regulatory approval may be delayed, limited, or subject to burdensome conditions.
• Dependence on third parties for services and raw materials needed for manufacturing, and for product distribution if commercialized, with risks of non-performance or supply interruptions.
• Use of third-party manufacturers may increase the risk of inadequate quantities of investigational product candidates.
• Reliance on third parties to conduct preclinical studies and clinical trials, with risks of non-performance, missed deadlines, or non-compliance with regulatory requirements.
• Future third-party manufacturers will likely be dependent upon their own third-party suppliers, making the company vulnerable to supply shortages and price fluctuations.
• Interim, topline, and preliminary data from clinical trials may change as more data become available and are subject to audit and verification procedures.
• Expending limited resources to pursue a particular investigational product candidate or indication may lead to failure to capitalize on other potentially more profitable opportunities.
• The U.S. FDA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.
• Obtaining and maintaining regulatory approval of a product in one jurisdiction does not guarantee success in obtaining or maintaining regulatory approval in other jurisdictions.
• The FDA and other regulatory authorities actively enforce laws and regulations prohibiting the promotion of off-label uses, which could lead to significant liability if violated.
• If required by the FDA to obtain approval of a companion diagnostic test, delays or failure to obtain such approval could materially impair revenue generation.
• Expedited review programs (RMAT, Fast Track) do not guarantee faster development or approval, and designations can be rescinded.
• The FDA's Rare Pediatric Disease Designation for HLHS does not guarantee a priority review voucher, nor does Orphan Drug Designation guarantee seven years of market exclusivity.
• Difficulties may arise from changes to current regulations and future legislation, both in the U.S. and in other foreign jurisdictions.
• Relationships with healthcare professionals, clinical investigators, CROs, and payors may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws.
• Inadequate funding for the FDA, SEC, and other government agencies could hinder their ability to hire and retain key personnel, preventing timely development or commercialization.
• Business activities involve the use of hazardous materials, which could expose the company to environmental and other liability.
• The company may not be successful in its efforts to identify or discover additional investigational product candidates in the future.
• Risks associated with marketing investigational product candidates internationally, including differing regulatory requirements, economic weakness, political instability, and compliance with anti-bribery laws.
• The increasing use of social media platforms presents new risks and challenges, including potential for adverse event reporting, negative publicity, and regulatory scrutiny.
• The ability to utilize net operating loss carryforwards and certain other tax attributes may be limited.
• The price of Class A common stock has been, and may continue to be, volatile, potentially resulting in substantial or total losses for investors.
• There may not be sufficient liquidity in the market for the company's securities for investors to sell their shares.
• The company will need to raise substantial additional funding, and inability to do so could force delays, scaling back, or discontinuation of development programs.
• Failure to meet Nasdaq listing requirements could result in delisting from trading on Nasdaq.
• The dual-class structure of common stock may adversely affect the trading market for Class A common stock.
• Holders of Class B common stock exert considerable control over the direction of the business.
• If securities or industry analysts do not publish research or publish negative, adverse, or misleading reports, the Class A common stock price and trading volume could decline.
• FINRA sales practice requirements may limit a stockholder's ability to buy and sell the company's securities.
• Provisions in the Certificate of Incorporation, Bylaws, and Delaware law might discourage, delay, or prevent a change in control or changes in management.
• As an emerging growth company, reduced reporting requirements may make Class A common stock less attractive to investors.
• The issuance of additional stock in connection with acquisitions or otherwise will dilute all other stockholdings.
• The company has never commercialized an investigational product candidate before and may lack the necessary expertise, personnel, and resources to successfully commercialize any products on its own.
• The company may be required to implement employee furloughs or other workforce reductions, which could adversely affect its business, financial condition, and results of operations.
• Difficulties in managing organizational growth.
• Computer systems, or those of third parties, may fail or suffer security or data privacy breaches or other unauthorized access.

Future Outlook

Longeveron anticipates top-line trial results for its ELPIS II (HLHS) study in Q3 2026, with a potential Biologics License Application (BLA) filing with the FDA in 2027 and plans to seek a commercialization partner if successful. The company will continue in-depth analyses of its Alzheimer's disease (AD) data to refine its clinical development strategy and is focused on seeking partnership opportunities and/or non-dilutive funding for the AD program, including a proposed single, pivotal, seamless adaptive Phase 2/3 clinical trial. Planning and preparation for a Phase 2 pivotal registrational clinical trial for pediatric Dilated Cardiomyopathy (DCM) are set to begin in 2026, with initiation in 2027. The company plans to utilize a CDMO for commercial-scale production of HLHS, while leveraging its Miami facility for early-phase clinical supply and process development. It intends to advance BLA-enabling CMC activities and continue to improve and expand manufacturing capabilities for cost-effective production. Longeveron will also be opportunistic in pursuing collaborations and in-licensing opportunities to expand its pipeline and intellectual property. The company expects operating expenses to increase and will require additional capital, with current funding projected to last into Q4 2026. Temporary executive compensation reductions are anticipated to be restored once sufficient financing is secured.

Management Comments

• Our mission is to continue to advance the development and regulatory approval of laromestrocel in order to make it available for patients who may need it.
• We believe this approach [using a CDMO for commercial manufacturing] offers a more cost-effective and timely path to support our potential BLA submission and commercial launch.
• Our current objective is to forge strategic collaborations and/or partnerships for the advancement of laromestrocel in all four potential indications.
• If the current ELPIS II trial in HLHS is successful, we believe the timing would be optimal to seek a potential BLA filing with the FDA in 2027 and commercialization partner.
• Our overarching objective is to advance laromestrocel through strategic collaborations and partnerships, with the goal of addressing the significant unmet medical need in AD.
• We have prepared a cash flow forecast which indicates that we do not have sufficient cash to meet our minimum expenditure commitments for one year from the date these financial statements are available to be issued and therefore we need to raise additional funds to continue as a going concern.

Industry Context

StockSavvy.ai notes that Longeveron operates in the highly competitive and rapidly evolving regenerative medicine sector, which includes gene therapies, cell therapies, and tissue-engineered products. The FDA's approval of Mesoblast's Ryoncil, an allogeneic bone marrow-derived MSC therapy, is a significant positive precedent for Longeveron, validating the regulatory pathway for this class of treatment. However, the Alzheimer's disease therapeutic area has a historically high failure rate, and regulatory agencies apply heightened scrutiny, making Longeveron's AD program particularly challenging. The lack of a consensus definition for 'Aging-related Frailty' also presents a unique regulatory hurdle compared to more established disease indications. The broader macroeconomic environment, including inflation and geopolitical instability, also poses risks to the company's financial stability and access to capital.

Comparison to Industry Standards

• Mesoblast's Ryoncil (remestemcel-L-rknd), an allogeneic bone marrow-derived MSC therapy, received FDA approval on December 18, 2024, for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients. This marks the first FDA-approved MSC therapy, providing a positive precedent for Longeveron's laromestrocel, which is also an allogeneic bone marrow-derived MSC therapy, potentially easing its regulatory path.
• The Alzheimer's disease (AD) drug development landscape is characterized by a historically high failure rate, with many investigational therapies failing in late-stage clinical trials. Longeveron's laromestrocel is noted as the only investigational product candidate to be granted Regenerative Medicine Advanced Therapy (RMAT) designation for mild AD to date, which could potentially accelerate its development and review compared to other AD candidates, such as those targeting amyloid beta like aducanumab or lecanemab, which have faced significant scrutiny regarding clinical benefit and reimbursement.
• The lack of a universally accepted definition for 'Aging-related Frailty' and the absence of FDA-approved conventional drugs or therapies for this indication mean Longeveron faces a unique challenge in establishing regulatory precedents, unlike companies targeting well-defined diseases with established treatment paradigms. This contrasts with more mature therapeutic areas where clinical endpoints and regulatory pathways are well-defined.

Management Changes

Corporate Governance

Legal Proceedings

• As of December 31, 2025, the company is not aware of any legal proceedings or material developments requiring disclosure.
• The company acknowledges that litigation is inherently unpredictable, and an unfavorable resolution of any future disputes could materially affect its future results of operations, cash flows, or financial condition.

Related Party Transactions

• **CSO Consulting Services Agreement**: With Dr. Joshua Hare (Co-Founder, Chief Science Officer, Executive Chairman). Annual payment of $265,000 for part-time services. The initial term ended November 22, 2024, and the agreement continues on a month-to-month basis. Deferred payment of 2024 and 2025 consulting fees (to be paid in February 2027 and February 2028, respectively).
• **Cash-for-Equity Program**: Dr. Hare received stock options in March and April 2025 as settlement for approximately $45,000 in previously accrued consulting fees and his 2024 performance bonus of approximately $131,000. He also received stock options in July 2025 for $30,000 in consulting fees.
• **JMHMD License Agreement**: An exclusive license agreement with JMH MD Holdings, LLC (an affiliate of Dr. Joshua Hare) for CD271 cellular therapy technology. Requires a 1% running royalty on annual net sales of licensed products and 10% of net sales from sub-licensees. No license fees were due in 2025 or 2024.
• **University of Miami (UM) License Agreements**: The company has two exclusive license agreements with UM (where Dr. Joshua Hare is employed and developed the technology). The first (November 20, 2014) for Aging-related Frailty MSC technology requires a 3% running royalty on annual net sales, escalating annual cash payments up to $50,000, and milestone payments ($500,000 each) upon Phase 3 completion, BLA approval, and first commercial sale. Accrued $7,500 in milestone fees payable to UM as of December 31, 2025. The second (July 18, 2024) for UMP-144 technology requires initial payments, reimbursement of patent expenses, an annual $10,000 fee (waived if current on other UM fees), and additional milestones ($150,000 upon Phase 3 completion, $250,000 upon BLA/NDA issuance). No milestone fees were accrued as of December 31, 2025.
• **Alzheimer's Association Grant Award**: Under the grant award agreement, the company may be required to make revenue sharing or distribution of revenue payments for products or inventions generated or resulting from this clinical trial program, with potential payments up to five times the $3.0 million award amount.
• **Participation in Capital Markets Transactions**: J. Nathaniel Powell (former Interim CEO), Lisa A. Locklear (CFO), and Khoso Baluch (former Director) participated in the public offering on August 11, 2025, though the amount involved for each did not exceed $120,000.
• **Indemnification Agreements**: The company has indemnification agreements with each of its directors and executive officers.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing and future capital raises, as well as potential volatility in the stock price. The company's Nasdaq non-compliance and 'going concern' doubt could lead to reduced liquidity and further price declines. The dual-class stock structure concentrates voting power, limiting influence for Class A shareholders.
• **Employees**: Subject to temporary compensation reductions for executives and potential for broader workforce reductions or furloughs, which could negatively impact morale, productivity, and the ability to attract and retain talent.
• **Patients/Customers**: Potential for new regenerative medicine therapies for unmet medical needs in HLHS, AD, and pediatric DCM, but also risks of clinical trial failures, delays in regulatory approval, or commercialization challenges that could limit access to these treatments.
• **Suppliers/CDMOs**: Continued reliance on third-party suppliers for critical raw materials and a strategic shift to CDMOs for commercial manufacturing for HLHS means these partners are crucial to the company's operational success and supply chain stability.
• **Creditors**: The explicit 'substantial doubt about our ability to continue as a going concern' raises significant credit risk, potentially impacting the company's ability to secure debt financing on favorable terms.

Next Steps

• Anticipate top-line trial results for the ELPIS II (HLHS) study in Q3 2026.
• Prepare for a potential Biologics License Application (BLA) filing with the FDA for HLHS in 2027.
• Seek a commercialization partner for HLHS if the ELPIS II trial is successful.
• Continue in-depth analyses of Alzheimer's disease (AD) data to refine the clinical development strategy.
• Seek partnership opportunities and/or non-dilutive funding for the AD program, including a proposed single, pivotal, seamless adaptive Phase 2/3 clinical trial.
• Begin planning and preparation in 2026 for a Phase 2 pivotal registrational clinical trial for pediatric Dilated Cardiomyopathy (DCM) in 2027.
• Expand manufacturing capabilities, including utilizing a CDMO for commercial-scale production for HLHS.
• Advance BLA-enabling Chemistry, Manufacturing and Controls (CMC) activities, including process and analytical method validation planning and commercial production planning.
• Explore co-development, out-licensing, or other collaboration agreements for commercialization.
• Actively explore promising potential additions to the pipeline through internal research and development and in-licensing.
• Continue to expand the intellectual property portfolio.
• Monitor the closing bid price of Class A common stock and assess available options to regain compliance with Nasdaq's Minimum Bid Price Requirement.
• Appoint, or submit to stockholders for election, at least one independent director who qualifies as an audit committee financial expert at the earlier of the next annual shareholders meeting or within the 180-day cure period.
• Repay the members of the executive leadership team an amount equal to the difference between their base salary in effect immediately prior to the temporary reduction and the reduced salary paid, contingent upon the company's financial ability.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by recurring losses, negative cash flow, and an accumulated deficit of $132.3 million, leading to a 'substantial doubt about our ability to continue as a going concern' from both management and auditors. While there is clinical progress and positive regulatory designations for its lead product candidate, laromestrocel, the company's immediate liquidity is extremely limited, with cash only funding operations into Q4 2026 even after a recent $15.9 million capital raise. The need for continuous, substantial additional financing, coupled with Nasdaq compliance issues and temporary executive compensation cuts, indicates a high-risk investment profile with significant uncertainty regarding long-term viability and potential for further shareholder dilution.

Keywords

Biotechnology, Regenerative Medicine, Cell Therapy, Laromestrocel, Lomecel-B, HLHS, Alzheimer's Disease, Pediatric Dilated Cardiomyopathy, Aging-related Frailty, Clinical Trials, FDA, RMAT, Orphan Drug, Fast Track, SEC Filing, 10-K, Nasdaq, Going Concern, Capital Raise, Drug Development, Mesenchymal Stem Cells (MSCs), Biologics License Application (BLA)